The current HealthTech Fundraising Landscape in the UK

Lloyd Price
9 hours ago
5 min read

The HealthTech fundraising landscape in the UK is dynamic and has seen significant activity recently, with a mix of opportunities and ongoing challenges.

Overall Landscape & Investment Trends (2024-2025)

Strong Valuation and Funding: UK health tech startups were valued at £32 billion at the end of 2024, having collectively raised £27.4 billion in funding (averaging £9.6 million per company).
Continued Growth: Q1 2025 saw UK HealthTech and life sciences startups raise £1.4 billion in venture capital investment, marking the sector's second strongest quarter on record and an 8% increase
compared to Q1 2024. Health was the most funded sector in the UK by a significant margin.
AI-Driven Investment: Nearly half of all VC investment in the health sector in Q1 2025 went to AI-powered startups, highlighting the technology's increasing influence and perceived potential. AI is expected to drive higher precision, accuracy, and autonomy in healthcare.
Biopharmaceuticals Leading: Within HealthTech, biopharmaceuticals remains the most valuable and populous sub sector, with companies raising a combined £11.9 billion during 2024.
Rebound from Post-COVID Lag: The life sciences venture funding in the UK and Nordics experienced a pivotal year in 2024, signaling a rebound after the post-COVID downturn. Average deal size increased by 32% year-over-year, and overall venture deployment increased by 18.9%.
Early and Growth Stage Activity: Early-stage funding (seed and Series A) has stabilised, while most UK venture capital in Q1 2025 was raised at the breakout stage (Series B and C).
Promising Sub-sectors: Women's health (which saw a unicorn), alternative care approaches, and provider operations companies (largely driven by AI and potential for healthcare system savings) attracted significant interest in 2024.
Geographical Hubs: The UK's "Golden Triangle" (London, Oxford, Cambridge) remains a key epicenter for Biopharma/DxTools activity.

Notable Funding Rounds (Recent Examples)

Verdiva Bio: Raised a £333.5 million Series A round in early 2025 for its Ozempic challenger.
Lindus Health: Secured a $55 million Series B in January 2025 for its clinical trials platform.
Nuclera: Raised a £57 million Series C in October 2024 for its desktop bioprinter for drug discovery.
ZOE: Raised £11.7 million in July 2024, backed by US-based fund Coefficient Capital.
Healx: Secured a £34.5 million investment in August 2024.
Peppy: Raised £37 million in Series B funding in 2023.
GetHarley: Secured £42 million in Series B funding in 2023.

Challenges and Barriers to Investment

Access to Funding for SMEs: Despite efforts, access to funding remains a critical obstacle for many UK HealthTech SMEs. They often lack the financial muscle and resources for cutting-edge R&D and face high costs for testing and compliance, such as clinical trials.
NHS Procurement: Selling into the NHS continues to be a significant hurdle. Procurement processes are often slow, fragmented, and lack transparency, with regional variations, stifling innovation and disadvantaging SMEs.
Regulatory Hurdles: The complex regulatory landscape (GDPR, MHRA guidelines) can increase development costs and delay time to market, making the sector less attractive to some investors. Regulatory uncertainties have led half of the companies surveyed to delay bringing new innovations to the UK.
Rising Costs: Costs in regulation, sustainability compliance, freight services, and labor have all risen, putting pressure on the sector
.
Investor Risk Aversion: HealthTech often requires significant upfront investment and a longer timeline for returns, which can make investors risk-averse, especially for early-stage companies. Many investors may also lack specific expertise in evaluating HealthTech ventures.
Data Privacy and Security: Ensuring data privacy and security (e.g., GDPR compliance) is paramount but can be burdensome and costly.
Talent Acquisition: Attracting the right talent in the competitive UK healthcare tech sector, especially with the implications of Brexit on talent mobility, remains a challenge.
Evidence Gap: Conducting rigorous clinical trials and gathering real-world evidence to demonstrate efficacy and safety can be time-consuming and expensive.
Valuation Gap: HealthTech companies often have unique business models that may not fit traditional valuation frameworks, making it difficult to quantify long-term value.

Opportunities and Drivers of Growth

Government Support & Initiatives: Innovate UK, NIHR (National Institute for Health Research), and other government-backed programs offer funding and support for R&D, innovation projects, and commercialization pathways. The Life Sciences Innovative Manufacturing Fund (LSIMF) also provides significant funding.
NHS Innovation and Adoption Strategy: Industry sees optimism in initiatives that could be included in the upcoming NHS Innovation and Adoption Strategy, particularly clarity on real-world evidence development and dedicated local resources for innovation.
AI and Digital Transformation: The increasing integration of AI/ML, IoT, data analytics, and robotics is expected to drive further precision and efficiency in healthcare. AI-powered platforms can accelerate drug discovery, enhance precision medicine, and optimise workflows.
Personalised Medicine and Digital Twins: Advancements in processing and integrating multiomic data, combined with AI, are bringing personalised care closer, with patient digital twins offering powerful predictive capabilities.
Focus on Specific Health Needs: Opportunities exist in areas like women's health, mental health, and solutions for improving operational efficiencies within healthcare systems.
Non-dilutive Funding: UK startups are increasingly looking beyond equity to alternative sources of funding, with debt funding surging in Q1 2025.
Strong UK Research Base: The UK is seen as attractive globally for its research-friendly environment and ability to evaluate technologies for their clinical and cost-effectiveness, thanks to institutions like NIHR and NICE.

In summary, while the UK HealthTech sector faces persistent challenges related to funding access for SMEs, complex regulatory environments, and NHS procurement, it continues to be a strong and growing area, particularly driven by significant investment in AI and biopharmaceuticals, and supported by various government initiatives.

Nelson Advisors > Healthcare Technology M&A

Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions & partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide